As such, we sought to interrogate the consequences of Setd2 inactivation in KRAS-driven lung adenocarcinoma in order to better understand how SETD2 deficiency drives early and widespread tumor growth and identify intrinsic therapeutic vulnerabilities that may exist. This evidence concerns the gene KRAS and lung adenocarcinoma.